Your browser doesn't support javascript.
loading
An up to date on clinical prospects and management of osteoarthritis.
Maqbool, Mudasir; Fekadu, Ginenus; Jiang, Xinchan; Bekele, Firomsa; Tolossa, Tadesse; Turi, Ebisa; Fetensa, Getahun; Fanta, Korinan.
Afiliação
  • Maqbool M; Department of Pharmaceutical Sciences, University of Kashmir, Hazratbal Srinagar, 190006, Jammu and Kashmir, India.
  • Fekadu G; School of Pharmacy, Faculty of Medicine, The Chinese University of Hong Kong, Shatin, N.T, Hong Kong.
  • Jiang X; School of Pharmacy, Institute of Health Sciences, Wollega University, Nekemte, Ethiopia.
  • Bekele F; School of Pharmacy, Faculty of Medicine, The Chinese University of Hong Kong, Shatin, N.T, Hong Kong.
  • Tolossa T; Department of Pharmacy, College of Health Science, Mettu University, Mettu, Ethiopia.
  • Turi E; Department of Public Health, Institute of Health Sciences, Wollega University, Nekemte, Ethiopia.
  • Fetensa G; Department of Public Health, Institute of Health Sciences, Wollega University, Nekemte, Ethiopia.
  • Fanta K; School of Nursing and Midwifery, Institute of Health Sciences, Wollega University, Nekemte, Ethiopia.
Ann Med Surg (Lond) ; 72: 103077, 2021 Dec.
Article em En | MEDLINE | ID: mdl-34868573
ABSTRACT
The rising prevalence of osteoarthritis (OA) in the general population has necessitated the development of novel treatment options. It is critical to recognize the joint as a separate entity participating in degenerative processes, as well as the multifaceted nature of OA. OA is incurable because there is currently no medication that can stop or reverse cartilage or bone loss. As this point of view has attracted attention, more research is being directed toward determining how the various joint components are impacted and how they contribute to OA pathogenesis. Over the next few years, several prospective therapies focusing on inflammation, cartilage metabolism, subchondral bone remodelling, cellular senescence, and the peripheral nociceptive pathway are predicted to transform the OA therapy landscape. Stem cell therapies and the use of various biomaterials to target articular cartilage (AC) and osteochondral tissues are now being investigated in considerable detail. Currently, laboratory-made cartilage tissues are on the verge of being used in clinical settings. This review focuses on the update of clinical prospects and management of osteoarthritis, as well as future possibilities for the treatment of OA.
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Risk_factors_studies Idioma: En Ano de publicação: 2021 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Risk_factors_studies Idioma: En Ano de publicação: 2021 Tipo de documento: Article